ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0678

AKI Is Related to Mortality in COVID-19 Patients Without Underlying Kidney Disease

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Yu, Yue, Xiangya Hospital Central South University, Changsha, Hunan, China
  • Ge, Huipeng, Xiangya Hospital Central South University, Changsha, Hunan, China
  • Wang, Xiufen, Xiangya Hospital Central South University, Changsha, Hunan, China
  • Tao, Lijian, Xiangya Hospital Central South University, Changsha, Hunan, China
  • Peng, Zhangzhe, Xiangya Hospital Central South University, Changsha, Hunan, China
  • Xiao, Xiangcheng, Xiangya Hospital Central South University, Changsha, Hunan, China
Background

Due to its high infectivity and mortality, coronavirus disease 2019 (COVID-19) has become a global public health issue. The kidneys act as critical metabolic organs, therefore, whether COVID-19 can induce renal damage is of utmost importance but remains controversial, and the prognosis of COVID-19 encountering acute kidney injury (AKI) is unknown. Moreover, the efficacy of different treatments that COVID-19 patients undergo needs to be explored. In this study, we aimed to explore these questions.

Methods

A single-centered, retrospective study was conducted in which 96 patients with COVID-19 were enrolled. Epidemiological, clinical, and laboratory characteristics, as well as treatments and patient outcomes were described. Characteristics were compared between severe cases and critical cases. Relevant factors of AKI were filtrated, and the treatment efficacy was also evaluated.

Results

A total of 6 patients (6.3%) died during hospitalization. Four patients (4.2%) developed AKI, among which 3 patients (75%) died. Statistical analysis indicated that AKI was not common in COVID-19 patients without underlying kidney disease, but was related to mortality. Age, severity of disease, procalcitonin, C-reactive protein and interleukin-6 were correlated with AKI onset in COVID-19 patients, while lymphocyte count and estimated glomerular filtration rate at admission were inversely related to the development of AKI.

Conclusion

In conclusion, AKI is not common in COVID-19 patients without underlying kidney disease but related to mortality.

The relationship between AKI and outcome of study population
 Total(n=96)AKI(n=4)Non-AKI(n=92)P-value
outcome   0.001**
dead633 
survivor90189 

**-P≤0.001

Funding

  • Government Support - Non-U.S.